Phase II study investigating the efficacy of daratumumab in patients with stage 3B AL amyloidosis

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines early results from a Phase II study evaluating the safety and efficacy of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain (AL) amyloidosis (NCT04131309). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.